Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study

Blood (2024) 144 (Supplement 1): 966.

https://doi.org/10.1182/blood-2024-201784

Published: 2024

Journal Articles

Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

Marissa Morales Del Real, John H. Baird, Lu Chen, Joo Y. Song, Xiuli Wang, Swetha Kambhampati, Alan Macias, Emanuela C Marcucci, Soungchul Cha, Zhenyuan Dong, Teresa Kim, Baishakhi Barva, Sandrine Puverel, Qing Liu-Michael, Hazel Ting-Ying Cheng, Stephen J. Forman, Larry W. Kwak, Lihua E. Budde

Blood (2024) 144 (Supplement 1): 3127.

https://doi.org/10.1182/blood-2024-198416

Published: 2024

Journal Articles

Comparing Phenotyping, Gene Expression, and Function of T Lymphocytes before Mobilization Chemotherapy Versus after Stem Cell Harvesting in Patients with B Cell Lymphoma and Multiple Myeloma

Sheng-Hsuan Chien, Xiuli Wang, Wen-Chun Chen, Chun-Yu Liu

Blood (2023) 142 (Supplement 1): 2147.

https://doi.org/10.1182/blood-2023-173443

Published: 2023

Journal Articles

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

Blood (2023) 142 (Supplement 1): 1814.

https://doi.org/10.1182/blood-2023-179043

Published: 2023

Journal Articles

Generation of Bi-Specific Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of AIDS-Related B Cell Malignancies from Healthy Donors and HIV Patients

Saghar Pahlavanneshan, Ryan Urak, Ryotaro Nakamura, John Zaia, John H. Baird, Mary C Clark, Stephen J. Forman, Xiuli Wang

Blood (2023) 142 (Supplement 1): 6822.

https://doi.org/10.1182/blood-2023-173757

Published: 2023

Journal Articles

Development of Humanized CD19-Chimeric Antigen Receptor for B Cell Malignancy

Vibhuti Vyas, Lawrence Stern, Laura Lim, Christian Huynh, Ryan Urak, John C Williams, Stephen J Forman, Christine E Brown, Xiuli Wang

Blood (2022) 140 (Supplement 1): 12704–12705.

https://doi.org/10.1182/blood-2022-169803

Published: 2022

Journal Articles

Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells

Blood (2022) 140 (Supplement 1): 4615–4616.

https://doi.org/10.1182/blood-2022-163439

Published: 2022

Journal Articles

Antimetabolite Resistant CAR T Cells through the Suppression of Hypoxanthine Phosphoribosyltransferase 1

Ryan Urak, Stephen J Forman, Xiuli Wang

Blood (2022) 140 (Supplement 1): 10648–10649.

https://doi.org/10.1182/blood-2022-169583

Published: 2022

Journal Articles

Results from a Phase 1 Study to Evaluate a Memory-Enriched CD19-Specific CAR T Cell Platform in Adult Patients with CD19+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Tanya Siddiqi, Xiuli Wang, M. Suzette Blanchard, Jamie Wagner, Vibhuti Vyas, Mary C. Clark, Sandra Thomas, Baishakhi Barva, Angelica Gamez, Leslie L. Popplewell, Alex F. Herrera, Elizabeth Budde, Liana Nikolaenko, Christine E Brown, Stephen J Forman

Blood (2021) 138 (Supplement 1): 2836.

https://doi.org/10.1182/blood-2021-147082

Published: 2021

Journal Articles

Dexamethasone Enhanced CAR T Cell Persistence and Function through Upregulation of Interleukin 7 Receptor

Ryan Urak, Ashlie Munoz, Hui-Ju Hsieh, Ellie Taus, Stephen J Forman, Xiuli Wang

Blood (2021) 138 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2021-153507

Published: 2021

Journal Articles

Developing a Safer Anti-CD44v6 Chimeric Antigen Receptor T Cell Against Hematological Cancers By Mitigating on-Target Off-Tumor Toxicity

Dennis Awuah, Lawrence Stern, Ian Schrack, Tae Yoon Kim, Joseph Cohen, Ryan Urak, Christian Huynh, Wen-Chung Chang, Stephen J Forman, Xiuli Wang

Blood (2021) 138 (Supplement 1): 2796.

https://doi.org/10.1182/blood-2021-153927

Published: 2021

Journal Articles

CD19/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia

Xiuli Wang, Zhenyuan Dong, Wen-Chung Chang, Wesley Cheng, Vibhuti Vyas, Dennis Awuah, Soung-chul Cha, Aaron Anderson, Mary C. Clark, Stephen J Forman, Larry W. Kwak, Hong Qin

Blood (2021) 138 (Supplement 1): 2783.

https://doi.org/10.1182/blood-2021-151293

Published: 2021

Journal Articles

Single-Cell Analysis By Mass Cytometry Reveals CD19 CAR T Cell Spatiotemporal Plasticity in Patients

Lior Goldberg, Eric R Haas, Vibhuti Vyas, Ryan Urak, Stephen J Forman, Xiuli Wang

Blood (2021) 138 (Supplement 1): 2794.

https://doi.org/10.1182/blood-2021-153444

Published: 2021

Journal Articles

Results from a Phase 2 Study of a Novel Janus Kinase Inhibitor in Treatment of Patients with Myelofibrosis

Blood (2021) 138 (Supplement 1): 387.

https://doi.org/10.1182/blood-2021-145664

Published: 2021

Journal Articles

Myeloid cell–targeted miR-146a mimic inhibits NF-κB–driven inflammation and leukemia progression in vivo

Yu-Lin Su, Xiuli Wang, Mati Mann, Tomasz P. Adamus, Dongfang Wang, Dayson F. Moreira, Zhuoran Zhang, Ching Ouyang, Xin He, Bin Zhang, Piotr M. Swiderski, Stephen J. Forman, David Baltimore, Ling Li, Guido Marcucci, Mark P. Boldin, Marcin Kortylewski

Blood (2020) 135 (3): 167–180.

https://doi.org/10.1182/blood.2019002045

Published: 2020

Includes: Supplemental data

Journal Articles

CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma

Tanya Siddiqi, MD, Xiuli Wang, PhD, Joycelynne Palmer, PhD, Leslie L. Popplewell, MD FRCPA, Liana Nikolaenko, MD, Alex F. Herrera, MD, Lihua E Budde, MD PhD, Laura Lim, Vibhuti Vyas, MS, Christine E Brown, PhD, Stephen J. Forman, MD

Blood (2019) 134 (Supplement_1): 4075.

https://doi.org/10.1182/blood-2019-123765

Published: 2019

Journal Articles

Overcoming CD19 Antigen Loss in B-Cell Malignancies with CAR T Cells Targeting BAFF-R

Hong Qin, MD PhD, Zhenyuan Dong, PhD, Xiuli Wang, PhD, Wesley Cheng, BS, Diane Lynne Smith, PhD, Joo Y Song, MD, Ibrahim Aldoss, MD, Stephen J Forman, MD, Larry W Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 3871.

https://doi.org/10.1182/blood-2019-129228

Published: 2019

Journal Articles

Large-Scale Manufacturing of CMV-CD19CAR T Cells and Characterization of Their Biologic and Immunologic Properties

Xiuli Wang, PhD, Miriam Walter, Ryan Urak, Laura Lim, Vibhuti Vyas, MS, Sally Mokhtari, PhD, Don J. Diamond, PhD, Angelo Cardoso, PhD, John Zaia, MD, Stephen J. Forman, MD, Ryotaro Nakamura, MD

Blood (2019) 134 (Supplement_1): 3247.

https://doi.org/10.1182/blood-2019-131843

Published: 2019

Journal Articles

Adult Patients with ALL Treated with CD62L+ T Naïve/Memory-Enriched T Cells Expressing a CD19-CAR Mediate Potent Antitumor Activity with a Low Toxicity Profile

Samer K. Khaled, MD, Suzette Blanchard, PhD, Xiuli Wang, PhD, Jamie Wagner, BS, Araceli Naranjo, BS, Jennifer Simpson, Sandra Thomas, PhD, Julie Ostberg, PhD, Christine Brown, PhD, Stephen J Forman

Blood (2018) 132 (Supplement 1): 4016.

https://doi.org/10.1182/blood-2018-99-119883

Published: 2018

Journal Articles

CD19-CAR Therapy Using Naive/Memory or Central Memory T Cells Integrated into the Autologous Stem Cell Transplant Regimen for Patients with B-NHL

Leslie Popplewell, MD, Xiuli Wang, PhD, Suzette Blanchard, PhD, Jamie Wagner, BS, Araceli Naranjo, BS, Arencibia Adria, BS, Jinny Paul, PhD, Laura Lim, Wen-Chung Chang, PhD, Elizabeth E Budde, MD PhD, Sandra Thomas, PhD, Christine Brown, PhD, Stephen J Forman

Blood (2018) 132 (Supplement 1): 610.

https://doi.org/10.1182/blood-2018-99-119650

Published: 2018

NARROW

CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study

Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

Comparing Phenotyping, Gene Expression, and Function of T Lymphocytes before Mobilization Chemotherapy Versus after Stem Cell Harvesting in Patients with B Cell Lymphoma and Multiple Myeloma

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

Generation of Bi-Specific Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of AIDS-Related B Cell Malignancies from Healthy Donors and HIV Patients

Development of Humanized CD19-Chimeric Antigen Receptor for B Cell Malignancy

Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells

Antimetabolite Resistant CAR T Cells through the Suppression of Hypoxanthine Phosphoribosyltransferase 1

Results from a Phase 1 Study to Evaluate a Memory-Enriched CD19-Specific CAR T Cell Platform in Adult Patients with CD19+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Dexamethasone Enhanced CAR T Cell Persistence and Function through Upregulation of Interleukin 7 Receptor

Developing a Safer Anti-CD44v6 Chimeric Antigen Receptor T Cell Against Hematological Cancers By Mitigating on-Target Off-Tumor Toxicity

CD19/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia

Single-Cell Analysis By Mass Cytometry Reveals CD19 CAR T Cell Spatiotemporal Plasticity in Patients

Results from a Phase 2 Study of a Novel Janus Kinase Inhibitor in Treatment of Patients with Myelofibrosis

Myeloid cell–targeted miR-146a mimic inhibits NF-κB–driven inflammation and leukemia progression in vivo

CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma

Overcoming CD19 Antigen Loss in B-Cell Malignancies with CAR T Cells Targeting BAFF-R

Large-Scale Manufacturing of CMV-CD19CAR T Cells and Characterization of Their Biologic and Immunologic Properties

Adult Patients with ALL Treated with CD62L+ T Naïve/Memory-Enriched T Cells Expressing a CD19-CAR Mediate Potent Antitumor Activity with a Low Toxicity Profile

CD19-CAR Therapy Using Naive/Memory or Central Memory T Cells Integrated into the Autologous Stem Cell Transplant Regimen for Patients with B-NHL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only